Prolonged survival in fibrosing cholestatic hepatitis with long-term ganciclovir therapy.
A 45-yr-old man underwent liver transplantation for cirrhosis due to hepatitis B and developed recurrent infection. Serial liver biopsies revealed fibrosing cholestatic hepatitis, an entity that is associated with rapid graft failure, and this was treated with long-term intravenous ganciclovir therapy. The patient is alive and well 2 yr after transplantation, despite the presence of well-established cirrhosis and a marked accumulation of intrahepatic hepatitis B surface and core antigens. It is postulated that partial reduction of viral replication resulted in an incomplete syndrome in which rapid graft failure did not occur, but progressive fibrosis developed. Our case suggests that newer nucleoside analogues that provide a greater degree of inhibition to hepatitis B virus replication may greatly improve the outcome of patients with recurrent infection after liver transplantation.
Jamal
H
H
Section of Gastroenterology and Hepatology, Alton Ochsner Medical Institutions, New Orleans, Louisiana, USA.
Regenstein
F
F
Farr
G
G
Perrillo
R P
RP
D000998:Antiviral Agents / Q000627:therapeutic use*; D002780:Cholestasis, Intrahepatic / Q000150:complications / Q000188:drug therapy*; D015774:Ganciclovir / Q000627:therapeutic use*; D006084:Graft Rejection / Q000517:prevention & control; D006509:Hepatitis B / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D016031:Liver Transplantation / Q000276:immunology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications; D012008:Recurrence; D013997:Time Factors; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D015774:Ganciclovir